323 related articles for article (PubMed ID: 31212055)
1. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
6. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
[TBL] [Abstract][Full Text] [Related]
7. Combinational Chemoimmunotherapy for Breast Cancer by Codelivery of Doxorubicin and PD-L1 siRNA Using a PAMAM-Incorporated Liposomal Nanoplatform.
Hu Q; Yao J; Wang X; Wang Y; Fu X; Ma J; Lin H; Xu J; Shen L; Yu X
ACS Appl Mater Interfaces; 2022 Feb; 14(7):8782-8792. PubMed ID: 35138103
[TBL] [Abstract][Full Text] [Related]
8. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
9. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
10. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
11. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
[TBL] [Abstract][Full Text] [Related]
12. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
13. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer.
Han L; Huang R; Li J; Liu S; Huang S; Jiang C
Biomaterials; 2011 Feb; 32(4):1242-52. PubMed ID: 20971503
[TBL] [Abstract][Full Text] [Related]
14. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
15. ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy.
Pei P; Sun C; Tao W; Li J; Yang X; Wang J
Biomaterials; 2019 Jan; 188():74-82. PubMed ID: 30336287
[TBL] [Abstract][Full Text] [Related]
16. A tumor microenvironment responsive biodegradable CaCO
Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
18. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
19. Targeted Delivery of Doxorubicin via CD147-Mediated ROS/pH Dual-Sensitive Nanomicelles for the Efficient Therapy of Hepatocellular Carcinoma.
Qu C; Li J; Zhou Y; Yang S; Chen W; Li F; You B; Liu Y; Zhang X
AAPS J; 2018 Feb; 20(2):34. PubMed ID: 29476273
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
